Melanie Shulman
YOU?
Author Swipe
View article: Assessment of Baseline Plasma p‐tau217 in TANGO, a Randomized, Placebo‐controlled Phase 2 Study of Gosuranemab in Patients with Early Alzheimer’s Disease
Assessment of Baseline Plasma p‐tau217 in TANGO, a Randomized, Placebo‐controlled Phase 2 Study of Gosuranemab in Patients with Early Alzheimer’s Disease Open
Background TANGO was a Phase 2 clinical study designed to assess the safety and efficacy of gosuranemab, an anti‐tau monoclonal antibody, in participants with mild cognitive impairment due to Alzheimer’s disease (AD) or with mild AD dement…
View article: Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease Open
The Alzheimer's disease (AD) research community continues to make great strides in expanding approaches for early detection and treatment of the disease, including recent advances in our understanding of fundamental AD pathophysiology beyo…
View article: Design of a Phase 2, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia
Design of a Phase 2, Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia Open
Background BIIB080 (formerly IONIS MAPT‐RX) is an antisense oligonucleotide (ASO) designed to bind to MAPT pre‐mRNA, promote its degradation, and prevent translation of all forms of tau protein. BIIB080 is, to our knowledge, the first tau …
View article: TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease
TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease Open
View article: Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease
Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer Disease Open
Importance Accumulation of hyperphosphorylated, tangled microtubule-associated protein tau (MAPT) is a pathological hallmark of Alzheimer disease (AD) associated with disease progression and cognitive decline. Objective To evaluate the eff…
View article: Prognostic relevance of gait-related cognitive functions for dementia conversion in amnestic mild cognitive impairment
Prognostic relevance of gait-related cognitive functions for dementia conversion in amnestic mild cognitive impairment Open
View article: Identifying healthy individuals with Alzheimer’s disease neuroimaging phenotypes in the UK Biobank
Identifying healthy individuals with Alzheimer’s disease neuroimaging phenotypes in the UK Biobank Open
Background Identifying prediagnostic neurodegenerative disease is a critical issue in neurodegenerative disease research, and Alzheimer’s disease (AD) in particular, to identify populations suitable for preventive and early disease-modifyi…
View article: A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease
A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease Open
View article: Current directions in tau research: Highlights from Tau 2020
Current directions in tau research: Highlights from Tau 2020 Open
Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau‐related mechanisms as therapeutic targets. In February 2020, leading tau e…
View article: Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer’s disease
Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer’s disease Open
View article: Baseline characteristics from TANGO: Phase 2 study to evaluate gosuranemab (BIIB092) in patients with early Alzheimer’s disease
Baseline characteristics from TANGO: Phase 2 study to evaluate gosuranemab (BIIB092) in patients with early Alzheimer’s disease Open
Background Gosuranemab is a humanized monoclonal antibody binding tau at the N‐terminal domain. The TANGO study is a randomized, placebo‐controlled, global Phase 2 Study evaluating safety and clinical efficacy of gosuranemab in patients di…
View article: Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia
Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia Open
Introduction: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non-AD dementia and (2) determinants of progression …
View article: Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia
Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia Open
Introduction In this multicenter study on subjective cognitive decline (SCD) in community‐based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non‐AD dementia and (2) determinants of progression t…
View article: ACNP 57th Annual Meeting: Poster Session III
ACNP 57th Annual Meeting: Poster Session III Open
Background: There is growing evidence that the biological mechanisms of depression significantly overlap with those observed during the aging process, leading to an acceleration of brain and systemic aging in depressed individuals.In a pre…
View article: Supplementary Material for: Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial
Supplementary Material for: Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial Open
Background/Aims: The aim was to examine added benefits of a Comprehensive, Individualized, Person-Centered Management (CI-PCM) program to memantine treatment. Methods: This was a 28-week, clinician-blinded, rand…
View article: Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial
Comprehensive, Individualized, Person-Centered Management of Community-Residing Persons with Moderate-to-Severe Alzheimer Disease: A Randomized Controlled Trial Open
Background/Aims: The aim was to examine added benefits of a Comprehensive, Individualized, Person-Centered Management (CI-PCM) program to memantine treatment. Methods: This was a 28-week, clinician-blinded, rand…
View article: ACNP 55th Annual Meeting: Poster Session I
ACNP 55th Annual Meeting: Poster Session I Open